Solvay's strategy in biotech Solvay is not the first name that would come to mind if one were asked to put together a list of powerhouse pharmaceutical companies. But the Brussels-based member of the Solvay Group weighed in last week with two platform technology deals that mark its commitment to an aggressive drug discovery program using the latest in biotechnology. The group's Solvay Duphar B.V. company agreed to develop new drugs using